Improving CD3 bispecific antibody therapy in solid tumors using combination strategies

被引：0
|
作者：
Lloyd, Katy [1 ]
Middelburg, Jim [2 ]
Ovcinnikovs, Vitalijs [1 ]
Pencheva, Nora [1 ]
Kemper, Kristel [1 ]
van Hall, Thorbald [2 ]
机构：
[1] Genmab BV, Utrecht, Netherlands
[2] Leiden Univ, Oncode Inst, Med Ctr, Dept Med Oncol, Leiden, Netherlands
来源：
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词：
antibody; CD3; bispecific Ab; cancer; vaccination; T-CELL ENGAGER; CANCER; EXPANSION; CYTOTOXICITY; BLOCKADE; MYELOMA;
D O I：
10.3389/fonc.2025.1548446
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these recent advances, the success of CD3 bsAbs in solid cancer has been hampered by hurdles like limited intratumoral T cell numbers, immunosuppressive tumor microenvironments (TME), and poor memory T-cell induction. Furthermore, tumor surface antigen selection for an optimal therapeutic window and acceptable collateral damage to normal tissues is challenging. In this review, we discuss recent research investigating combination approaches aimed at improving CD3 bsAb efficacy in solid cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Preclinical development of DuoBody(R)-CD3xB7H4, a novel CD3 bispecific antibody for the treatment of solid cancers
    Koopman, Louise A.
    Alemdehy, Farshid
    Paauwe, Madelon
    Smits-de Vries, Laura
    Karaiskaki, Frosso
    Brandhorst, Marcel
    Franken, Patrick
    Plantinga, Theo S.
    Houtkamp, Mischa A.
    de Poot, Stefanie A. H.
    Breij, Esther C. W.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [22] A BISPECIFIC ANTIBODY FOR MUC16 AND CD3 HAS PRECLINICAL ANTITUMOR ACTIVITY
    不详
    CANCER DISCOVERY, 2019, 9 (08) : 994 - 994
  • [23] Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma
    Little, Jessica S.
    Hurtado, Rocio M.
    Boire, Nicholas
    Baden, Lindsey R.
    Laga, Alvaro C.
    Silk, Ann W.
    Jacobson, Caron A.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [24] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
    Lu, Chia-Yen
    Chen, Gregory J.
    Tai, Pei-Han
    Yang, Yu-Chen
    Hsu, Yu-Shen
    Chang, Mingi
    Hsu, Chuan-Lung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
  • [25] TARGETING LEUKEMIC STEM CELLS IN AML USING THE BISPECIFIC CD33/CD3 BITE® ANTIBODY AMG 330
    Krupka, C.
    Kufer, P.
    Kischel, R.
    Koehnke, T.
    Zugmaier, G.
    Baeuerle, P.
    Vick, B.
    Konstandin, N.
    Jeremias, I.
    Spiekermann, K.
    Riethmueller, G.
    Hiddemann, W.
    Subklewe, M.
    HAEMATOLOGICA, 2014, 99 : 526 - 526
  • [26] Targeting leukemic stem cells in AML using the Bispecific CD33/CD3 BiTE® antibody AMG 330
    Krupka, C.
    Koehnke, T.
    Lichtenegger, F.
    Altmann, T.
    Vick, B.
    Konstandin, N.
    Metzeler, K.
    Jeremias, I
    Spiekermann, K.
    Riethmueller, G.
    Hiddemann, W.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 114 - 114
  • [27] Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
    Leconet, Wilhem
    Liu, He
    Guo, Ming
    Le Lamer-Dechamps, Sophie
    Molinier, Charlotte
    Kim, Sae
    Vrlinic, Tjasa
    Oster, Murielle
    Liu, Fang
    Navarro, Vicente
    Batra, Jaspreet S.
    Noriega, Adolfo Lopez
    Grizot, Sylvestre
    Bander, Neil H.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (09) : 1927 - 1940
  • [28] Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
    Lopez-Albaitero, Andres
    Xu, Hong
    Guo, Hongfen
    Wang, Linlin
    Wu, Zhihao
    Tran, Hoa
    Chandarlapaty, Sarat
    Scaltriti, Maurizio
    Janjigian, Yelena
    de Stanchina, Elisa
    Cheung, Nai-Kong V.
    ONCOIMMUNOLOGY, 2017, 6 (03):
  • [29] Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy
    Middelburg, Jim
    Schaap, Gaby
    Sluijter, Marjolein
    Lloyd, Katy
    Ovcinnikovs, Vitalijs
    Schuurman, Janine
    van der Burg, Sjoerd H.
    Kemper, Kristel
    van Hall, Thorbald
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [30] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Wheeler, Christina
    Lucas, Matthew
    Xing, Charles
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
12345